Chronic kidney disease (CKD) is a global public healthcare concern in the pediatric
population, where glomerulopathies represent the second most common cause. Although …

Sodium–glucose co-transporter 2 (SGLT2) inhibitors have been tested in randomized
controlled trials (RCTs) in nearly 100 000 adults and are approved for adults with type 2 …

Sodium-glucose cotransporter-2 (SGLT2) is a sodiumdependent glucose transport protein,
and its inhibitors (SGLT2i-gliflozins) are indicated as an adjunct therapy to diet and exercise …

Originally developed for use in type 2 diabetes mellitus (T2DM), sodium–glucose co-
transporter-2 (SGLT2) inhibitors demonstrated diverse cardiovascular-and kidney-protective …

Sodium-glucose cotransporter 2 inhibitors (SGLT2is) were originally developed as glucose-
lowering agents. These medications function by inhibiting glucose and sodium reabsorption …

Chronic kidney disease (CKD) is a global health problem, affecting more than 850 million
people worldwide. The number of patients receiving renal replacement therapy (dialysis or …

In recent years, sodium-glucose co-transporter 2 inhibitors (SGLT2i) have demonstrated
beneficial renoprotective effects, which culminated in the recent approval of their use for …

Since their introduction as antidiabetic drugs, SGLT2 inhibitors (SGLT2i) have come a long
way, proving to be beneficial on cardiovascular and renal outcomes independently of …

Chronic kidney disease (CKD) is a serious, progressive condition associated with significant
patient morbidity. Hypertension control and use of renin-angiotensin system blockers are the …

Some of the most common conditions affecting people are kidney diseases. Among them,
we distinguish chronic kidney disease and acute kidney injury. Both entities pose serious …